Gilead Sciences Stock Today

GILD Stock  USD 84.59  0.42  0.50%   

Performance

22 of 100

 
Weak
 
Strong
Solid

Odds Of Distress

Less than 5

 
High
 
Low
Very Low
Gilead Sciences is trading at 84.59 as of the 4th of October 2024, a 0.50 percent increase since the beginning of the trading day. The stock's lowest day price was 83.98. Gilead Sciences has under 5 % chance of experiencing financial distress over the next 2 years and had a solid performance during the last 90 days. Note, on June 13, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of Gilead Sciences's common stock.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
22nd of January 1992
Category
Healthcare
Classification
Health Care
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company was incorporated in 1987 and is headquartered in Foster City, California. The company has 1.24 B outstanding shares of which 19.95 M shares are currently shorted by private and institutional investors with about 3.49 trading days to cover. More on Gilead Sciences

Moving against Gilead Stock

  0.81ERNA Eterna TherapeuticsPairCorr
  0.81BNR Burning Rock BiotechPairCorr
  0.78DYAI Dyadic InternationalPairCorr
  0.75PTN Palatin TechnologiesPairCorr
  0.74ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.7CDT Conduit PharmaceuticalsPairCorr

Gilead Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Chairman of the Board, CEODaniel ODay
Thematic Ideas
(View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, NASDAQ Biotechnology, SP 100 Index, SP 100, Nasdaq 100, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ 100 Pre, NASDAQ Composite, NASDAQ Composite Total, BETTERINVESTING 100 INDEX, BTRINVSTNG 100 INDEX, NASDAQ Health Care, Macroaxis Index, Corona Opportunity, Health Care, Biotechnology, Drug Manufacturers—General, Healthcare (View all Sectors)
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.320.4365
Way Down
Pretty Stable
Gross Profit Margin1.070.7799
Significantly Up
Pretty Stable
Total Current Liabilities11.8 B11.3 B
Sufficiently Up
Slightly volatile
Non Current Liabilities Total29.5 B28.1 B
Sufficiently Up
Slightly volatile
Total Assets65.2 B62.1 B
Sufficiently Up
Slightly volatile
Total Current Assets10.8 B16.5 B
Way Down
Pretty Stable
Debt Levels
Gilead Sciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Gilead Sciences' financial leverage. It provides some insight into what part of Gilead Sciences' total assets is financed by creditors.
Liquidity
Gilead Sciences currently holds 24.99 B in liabilities with Debt to Equity (D/E) ratio of 1.3, which is about average as compared to similar companies. Gilead Sciences has a current ratio of 1.4, which is within standard range for the sector. Note, when we think about Gilead Sciences' use of debt, we should always consider it together with its cash and equity.

Free Cash Flow

4.19 Billion
Gilead Sciences (GILD) is traded on NASDAQ Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA, United States, 94404 and employs 18,000 people. Gilead Sciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a current market capitalization of 104.79 B. Gilead Sciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.24 B outstanding shares of which 19.95 M shares are currently shorted by private and institutional investors with about 3.49 trading days to cover. Gilead Sciences currently holds about 6.14 B in cash with 8.01 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9.
Check Gilead Sciences Probability Of Bankruptcy
Ownership Allocation
Gilead Sciences has a total of 1.24 Billion outstanding shares. The majority of Gilead Sciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gilead Sciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gilead Sciences. Please pay attention to any change in the institutional holdings of Gilead Sciences as this could imply that something significant has changed or is about to change at the company. Please note that on June 13, 2024, Senator Tommy Tuberville of US Senate acquired under $15k worth of Gilead Sciences's common stock.
Check Gilead Ownership Details

Gilead Stock Institutional Holders

InstituionRecorded OnShares
Bank Of New York Mellon Corp2024-06-30
14.1 M
Northern Trust Corp2024-06-30
13 M
Legal & General Group Plc2024-06-30
12.4 M
Amundi2024-06-30
11.2 M
Ubs Asset Mgmt Americas Inc2024-06-30
11.1 M
Dimensional Fund Advisors, Inc.2024-06-30
10.4 M
Amvescap Plc.2024-06-30
10.1 M
Goldman Sachs Group Inc2024-06-30
9.2 M
Pacer Advisors, Inc.2024-06-30
7.9 M
Blackrock Inc2024-06-30
120.6 M
Vanguard Group Inc2024-06-30
115.3 M
View Gilead Sciences Diagnostics

Gilead Sciences Historical Income Statement

At present, Gilead Sciences' Gross Profit is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 20.5 B, whereas Interest Expense is forecasted to decline to about 534.5 M. View More Fundamentals

Gilead Stock Against Markets

Gilead Sciences Corporate Management

Johanna MercierChief Commercial OfficerProfile
Deborah TelmanGeneral AffairsProfile
Jacquie CFAVice RelationsProfile
Diane WilfongCorp VPProfile
Flavius MDExecutive ResearchProfile

Additional Information and Resources on Investing in Gilead Stock

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.554
Dividend Share
3.04
Earnings Share
0.82
Revenue Per Share
22.298
Quarterly Revenue Growth
0.054
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.